Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy.

In recent years, it has been demonstrated that many of the pervasive genetic defects throughout cancerogenesis occur in genes encoding chromatin regulators (CRs). We analyzed the distribution and characteristics of well-studied CRs across tens of tho…

Preview only. Read the full abstract at the source